Opko shares plunge after disappointing trial results for growth hormone drug Shares of Opko Health plunged in Tel Aviv yesterday after the U.S. company said its experimental drug for growth hormone deficiency in adults failed to provide a statistically significant benefit over a placebo in a late-stage study.